Figure 1
Radar chart: summary of agreement on aspects related to the efficacy, safety, and cost-effectiveness of the cardiovascular polypill. Cardiovascular polypill developed by the Centro Nacional de Investigaciones Cardiovascualres (CNIC), also known as CNIC-polypill. This polypill contains acetylsalicylic acid (100 mg), atorvastatin (20 or 40 mg), and ramipril (2.5, 5, or 10 mg) and available in 23 countries as Trinomia®, Sincronium®, or Iltria®. CHD: coronary heart disease, CVD: cardiovascular disease, MACE: major adverse cardiovascular event, RRR: relative risk reduction.
Figure 2
Radar chart: summary of agreement on aspects related to the implementation of the cardiovascular polypill at hospital discharge. Cardiovascular polypill developed by the Centro Nacional de Investigaciones Cardiovascualres (CNIC), also known as CNIC-polypill. This polypill contains acetylsalicylic acid (100 mg), atorvastatin (20 or 40 mg), and ramipril (2.5, 5, or 10 mg) and available in 23 countries as Trinomia®, Sincronium®, or Iltria®.
Table 1
Percentage of panelists ranking of importance of objectives to be accomplished for recommending the cardiovascular polypill on hospital discharge.
| STATEMENT | RANK 1 (MOST IMPORTANT, SCORES 1 AND 2)* | RANK 2 (NEUTRAL, SCORE 3)* | RANK 3 (LEAST IMPORTANT, SCORES 4 AND 5)* | |
|---|---|---|---|---|
| #21 | What is the level of importance of the following objectives of the cardiovascular polypill treatment recommended for CHD secondary prevention patients on hospital discharge? | |||
| Please assign the level of importance to each of the objectives on a scale from 1 to 5. 1 = the most important and 5 = the least important. | ||||
| To reduce the relative risk of acute myocardial infarction or stroke | 82.3% | 0.0% | 17.7% | |
| To reduce the relative risk of cardiovascular death | 82.3% | 5.9% | 11.8% | |
| To increase treatment adherence | 82.3% | 0.0% | 17.6% | |
| To control CVD risk factors | 79.4% | 0.0% | 20.6% | |
| To reduce polypharmacy/treatment burden | 79.4% | 2.9% | 17.7% | |
| To increase treatment satisfaction | 67.7% | 11.8% | 20.6% | |
| To reduce treatment cost | 64.6% | 26.5% | 8.8% | |
| To increase safety | 55.9% | 23.5% | 20.6% |
[i] Note: Neutral responses are shown for transparency. The ‘neutral’ column reflects participants who rated the statement as moderately important (score 3 in a 1 to 5 scale). A 0.0% indicates clear agreement (e.g., ‘to reduce risk of MI or stroke’); a higher percentage suggests varying stakeholder views and greater ambivalence about the importance of that statement (e.g., ‘to reduce treatment cost’). Consider all three columns together to assess the level of agreement.
Cardiovascular polypill developed by the Centro Nacional de Investigaciones Cardiovascualres (CNIC), also known as CNIC-polypill. This polypill contains acetylsalicylic acid (100 mg), atorvastatin (20 or 40 mg), and ramipril (2.5, 5, or 10 mg) and available in 23 countries as Trinomia®, Sincronium®, or Iltria®.
*Calculation based on 34 valid answers.
CHD, coronary heart disease; CVD, cardiovascular disease.
Table 2
Percentage of panelists ranking factors for the success of the cardiovascular polypill treatment after hospital discharge.
| STATEMENT | RANK 1 (MOST IMPORTANT, SCORES 1 AND 2)* | RANK 2 (NEUTRAL, SCORE 3)* | RANK 3 (LEAST IMPORTANT, SCORES 4 AND 5)* | |
|---|---|---|---|---|
| #29 | In your view, how important are the following factors for the success of the ‘at home’ cardiovascular polypill treatment after hospital discharge of secondary prevention patients with CHD? Please enter a number to indicate the importance of each factor on a scale from 1 to 5. 1 = the most important and 5 = the least important factor. | |||
| Effective doctor–patient communication | 100.0% | 0.0% | 0.0% | |
| Willingness to persist on medication | 94.6% | 2.7% | 2.7% | |
| Access to medications | 88.6% | 11.4% | 0.0% | |
| Satisfactory doctor–patient relationship | 86.5% | 13.5% | 0.0% | |
| Patient’s knowledge of the treatment | 83.3% | 11.1% | 5.6% | |
| Patient capacity to manage polypharmacy post-discharge | 83.3% | 8.3% | 8.3% | |
| Patient’s knowledge of the disease | 82.9% | 5.7% | 11.5% | |
| Patient medication-taking habits | 81.1% | 13.5% | 5.4% | |
| Social/family support | 80.0% | 11.4% | 8.6% | |
| Financial capacity | 75.0% | 22.2% | 2.8% |
[i] Note: Neutral responses are shown for transparency. The ‘neutral’ column reflects participants who rated the statement as moderately important (score 3 in a 1 to 5 scale). A 0.0% indicates clear agreement (e.g., ‘to reduce risk of MI or stroke’); a higher percentage suggests varying stakeholder views and greater ambivalence about the importance of that statement (e.g., ‘to reduce treatment cost’). Consider all three columns together to assess the level of agreement.
Cardiovascular polypill developed by the Centro Nacional de Investigaciones Cardiovascualres (CNIC), also known as CNIC-polypill. This polypill contains acetylsalicylic acid (100 mg), atorvastatin (20 or 40 mg), and ramipril (2.5, 5, or 10 mg) and available in 23 countries as Trinomia®, Sincronium®, or Iltria®.
*Calculation based on 37 valid answers.
CHD, coronary heart disease.